Unlike in ER-positive and HER2-positive breast cancers where tremendous improvements in clinical outcomes have been realized through the use of targeted agents, there are currently no approved targeted treatments for TNBC, other than PARP inhibitors in the small subset of patients with BRCA1 or BRCA2 mutant tumors. The gene discussed is ERBB2; the disease is breast carcinoma.